tirzepatide optic neuropathy GLP-1 medicine and non-arteritic anterior ischemic neuropathy: Literature review and perspectives Vision loss: GLP-1 drugs like

Others report no change

Patients often report improved positivity, motivation and concentration after starting peptide therapy for more balanced hormones

(2025) British Thyroid Foundation [accessed 15 January 2026] Mounjaro

We needed to clearly establish who Ro is and what we stand for, so that when people considered taking a step toward weight lossor encountered Ro again in the weeks and months that followedthey would recognize us, trust us, and choose us

R 2 = 97.15%) and treatment duration (b = 0.26

In Phase 2 clinical research, retatrutide demonstrated body weight reductions of up to 24.2% over 48 weeks, the largest reported for any incretin-based compound at that stage of development [8]